ReviewCurrent research in pharmacology and drug discovery2025
Advancing organ-on-chip systems: the role of microfluidics in neuro-cardiac research.
Review in Current research in pharmacology and drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Induced Pluripotent Stem Cell-Based Platforms for Cardiac-Related Pain Research: Molecular Mechanisms, Experimental Models, and Therapeutic Applications.International journal of molecular sciences · 2026Review
- A reproducible and physiologically relevant human iPSC-derived platform for in vitro modeling of the neurocardiac junction.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation.Biosensors · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neuro-cardiac junction is involved in many pathological conditions in humans, but no model currently allows translational studies to investigate its role. Animal models fail to accurately represent this interaction. This review explores the role of microfluidic technologies in advancing organ-on-chip systems that simulate neuro-cardiac interactions in a controlled environment. By offering precise control over cellular environments, microfluidic platforms significantly enhance the modeling of dynamic cardiac-neural cell interactions. These systems allow the development of more accurate and functional neuro-cardiac junctions, vital for investigating cardiovascular diseases and the neuronal impact in these pathologies. While traditional animal models and co-culture techniques have their merits, they are limited in replicating human-specific physiology. Recent innovations in microfluidics, in combination with human-induced pluripotent stem cell technology, provide more physiologically relevant models and address ethical concerns regarding animal use. This review emphasizes the potential of these advanced microfluidic models in improving disease modeling, drug screening, and therapeutic strategies, ultimately advancing personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.